Stay updated on Sitravatinib in Advanced Liposarcoma and Soft Tissue Sarcomas Clinical Trial
Sign up to get notified when there's something new on the Sitravatinib in Advanced Liposarcoma and Soft Tissue Sarcomas Clinical Trial page.

Latest updates to the Sitravatinib in Advanced Liposarcoma and Soft Tissue Sarcomas Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe record presents details for a completed Phase 2 trial evaluating sitravatinib in advanced liposarcoma and other soft tissue sarcomas, including participant criteria, study measures, and results-related information.SummaryDifference45%

- Check17 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The study-record page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” terminology and links to related updates. It appears above the unchanged 403 Forbidden study record.SummaryDifference1%

- Check31 days agoChange DetectedThe footer revision changes from v3.7.1 to v3.7.2; the page remains a 403 error screen.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer’s site revision marker changes from v3.7.0 to v3.7.1 while the study page continues to display a 403 error.SummaryDifference0.2%

- Check52 days agoChange DetectedThe study page now shows a 403 Forbidden error, replacing the expected content with an access-denied page. The page displays standard site chrome and a Home link, indicating restricted access to the study record.SummaryDifference0.5%

Stay in the know with updates to Sitravatinib in Advanced Liposarcoma and Soft Tissue Sarcomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sitravatinib in Advanced Liposarcoma and Soft Tissue Sarcomas Clinical Trial page.